TY - CHAP
T1 - Epigenetics in ovarian cancer
AU - Seeber, L. M.S.
AU - van Diest, Paulus Joannes
PY - 2012
Y1 - 2012
N2 - Ovarian cancer is the most lethal gynecological cancer. Due to few early symptoms and a lack of early detection strategies, most patients are diagnosed with advanced-stage disease. Most of these patients, although initially responsive, eventually develop drug resistance. In this chapter, epigenetic changes in ovarian cancer are described. Various epigenetic changes including CpG island methylation and histone modification have been identified in ovarian cancer. These aberrations are associated with distinct disease subtypes and present in circulating serum of ovarian cancer patients. Several epigenetic changes have shown promise for their diagnostic, prognostic, and predictive capacity but still need further validation. In contrast to DNA mutations and deletions, epigenetic modifications are potentially reversible by epigenetic therapies. Promising preclinical studies show epigenetic drugs to enhance gene re-expression and drug sensitivity in ovarian cancer cell lines and animal models.
AB - Ovarian cancer is the most lethal gynecological cancer. Due to few early symptoms and a lack of early detection strategies, most patients are diagnosed with advanced-stage disease. Most of these patients, although initially responsive, eventually develop drug resistance. In this chapter, epigenetic changes in ovarian cancer are described. Various epigenetic changes including CpG island methylation and histone modification have been identified in ovarian cancer. These aberrations are associated with distinct disease subtypes and present in circulating serum of ovarian cancer patients. Several epigenetic changes have shown promise for their diagnostic, prognostic, and predictive capacity but still need further validation. In contrast to DNA mutations and deletions, epigenetic modifications are potentially reversible by epigenetic therapies. Promising preclinical studies show epigenetic drugs to enhance gene re-expression and drug sensitivity in ovarian cancer cell lines and animal models.
KW - Epigenetic biomarkers
KW - Epigenetic therapies
KW - Histone modification
KW - Methylation
KW - MicroRNA
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=84859942964&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859942964&partnerID=8YFLogxK
U2 - 10.1007/978-1-61779-612-8_15
DO - 10.1007/978-1-61779-612-8_15
M3 - Chapter
C2 - 22359298
AN - SCOPUS:84859942964
SN - 9781617796111
T3 - Methods in Molecular Biology
SP - 253
EP - 269
BT - Cancer Epigenetics
ER -